UK markets open in 1 hour 48 minutes

Novavax, Inc. (NVAX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
53.82+2.15 (+4.16%)
At close: 04:00PM EDT
53.30 -0.52 (-0.97%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close51.67
Open51.91
Bid0.00 x 900
Ask0.00 x 900
Day's range50.20 - 55.47
52-week range34.88 - 277.80
Volume5,266,234
Avg. volume6,045,546
Market cap4.205B
Beta (5Y monthly)1.57
PE ratio (TTM)N/A
EPS (TTM)-17.51
Earnings date03 Aug 2022 - 08 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est155.17
  • Motley Fool

    3 Reasons to Buy Novavax and 1 to Sell

    Novavax (NASDAQ: NVAX) is a pandemic stock. Now it's down to $50, and the company's market cap is under $4 billion. Here are three arguments for buying Novavax stock and one reason for why you might want to avoid these shares.

  • Motley Fool

    5 Unique Stocks That Can Generate Transformational Wealth

    As much as you might hate to hear this, stock market corrections and bear markets are a perfectly normal part of the investing cycle. Including the current bear market decline that the benchmark S&P 500 and tech-focused Nasdaq Composite are navigating their way through, the broader market has dropped by a double-digit percentage, on average, every 1.85 years since the beginning of 1950. Despite corrections being commonplace, the amount of time Wall Street spends in a bull market handily outpaces periods of pessimism.

  • Motley Fool

    Why Sanofi May Be a Frontrunner in Endemic COVID-19

    Global biopharmaceutical company Sanofi (NASDAQ: SNY) encountered setbacks while developing its COVID-19 vaccine, and only this year reported results from late-stage clinical trials. Sanofi opted for the more traditional protein-based technology for its COVID-19 vaccine, Vidprevtyn, rather than the mRNA technology of Pfizer-BioNTech's Comirnaty and Moderna's Spikevax. The mRNA technology delivers genetic code instructing the body's cells to make the protein, while the more traditional approach produces the protein in a lab before injecting it into the body.